When the U.S. Food and Drug Administration’s Center for Tobacco Products (CTP) issued marketing denial orders (MDOs) for Suorin and Blu PLUS+ e-cigarette products, Tony Abboud, executive director of the Vapor Technology Association (VTA), said the decision was just the latest installment of the FDA and CTP’s efforts to implement its de-facto ban on e-cigarettes in the U.S.
The FDA’s largest reorganization in history, involving about 8,000 employees, is far more than just “moving some boxes around.” The proposed changes and updates to an FDA-wide reorganization plan have been out for external reviews and clearances since Dec. 13, 2023, and implementation should occur sometime during 2024.
What started as a crisis over the safety and supply of infant formula became a wide-ranging review of FDA’s food programs by the Reagan-Udall Foundation.
Public Workshop: In-Person and Virtual
February 21, 2024 | 10am-4pm (eastern)
The Food and Drug Administration’s Center for Tobacco Products (“CTP”) has released a strategic plan intended to guide the Center’s activity for the next five years.
